Realtime | Geld | Brief | Zeit |
---|---|---|---|
2,918 | 3,004 | 11:04 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Hansa Biopharma AB: Bulletin from the Extraordinary General Meeting in Hansa Biopharma AB (publ) | 140 | GlobeNewswire (Europe) | Lund, Sweden, September 2, 2025. Hansa Biopharma AB (publ), "Hansa" (Nasdaq Stockholm: HNSA), has today on September 2, 2025 held its Extraordinary General Meeting. The Extraordinary General Meeting... ► Artikel lesen | |
07.08. | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) | 2 | Cision News | ||
01.08. | Hansa Biopharma AB: Hansa Biopharma announces supportive data from treatment with imlifidase prior to the administration of gene therapy for Duchenne muscular dystrophy | 89 | GlobeNewswire (Europe) | Lund, Sweden, 1 August 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced topline results from three patients with Duchenne muscular dystrophy (DMD) treated with Hansa's imlifidase... ► Artikel lesen | |
29.07. | Hansa Biopharma Makes Leadership Appointments | 1 | Contract Pharma | ||
29.07. | Hansa Biopharma AB: Hansa Biopharma announces key executive appointments to support continued growth | 654 | PR Newswire | LUND, Sweden, July 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as Chief Legal Officer... ► Artikel lesen | |
17.07. | Hansa Biopharma Q2 2025 slides: 76% product sales growth amid pipeline advancement | 3 | Investing.com | ||
17.07. | Hansa Biopharma Q2 2025: Starke Produktverkäufe kompensieren verfehlte Prognosen | 3 | Investing.com Deutsch | ||
17.07. | Hansa Biopharma GAAP EPS of -SEK 2.53, revenue of SEK 49.1M | 1 | Seeking Alpha | ||
HANSA BIOPHARMA Aktie jetzt für 0€ handeln | |||||
17.07. | Hansa Biopharma AB: Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results | 280 | PR Newswire | Hansa secures directed cash share issue of approximately 232 MSEK/US $24.3M and restructures NovaQuest debt.As compared to prior year Q2 IDEFIRIX product sales increased 76%.LUND, Sweden... ► Artikel lesen | |
08.07. | Hansa Biopharma Names Chief Medical Officer | 1 | Contract Pharma | ||
08.07. | Hansa Biopharma Appoints Richard Philipson As CMO | - | RTTNews | ||
08.07. | Hansa Biopharma AB: Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer | 335 | PR Newswire | LUND, Sweden, July 8, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA) today announced that Dr. Richard Philipson has been appointed Chief Medical Officer (CMO)... ► Artikel lesen | |
03.07. | HANSA BIOPHARMA AB: Hansa Biopharma to host Q2 2025 interim results conference call | 2 | Cision News | ||
30.06. | Hansa Biopharma AB: Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London | 322 | PR Newswire | LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data... ► Artikel lesen | |
30.06. | HANSA BIOPHARMA AB: Hansa Biopharma: Increase in number of shares and votes | 3 | Cision News | ||
25.06. | Hansa Biopharma AB: Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) | 204 | GlobeNewswire (Europe) | Lund, Sweden, June 25, 2025. Hansa Biopharma AB (publ), "Hansa" (Nasdaq Stockholm: HNSA), has today on June 25, 2025 held its Annual General Meeting. The Annual General Meeting was held by physical... ► Artikel lesen | |
11.06. | Hansa Biopharma AB: Hansa Biopharma to attend BIO International Convention | 287 | PR Newswire | LUND, Sweden, June 11, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ Stockholm: HNSA), today announced that Hansa's CEO Renée Aguiar-Lucander will speak at the BIO International... ► Artikel lesen | |
09.06. | Hansa Biopharma AB: Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025 | 290 | PR Newswire | LUND, Sweden, June 9, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual investor event on Guillain-Barré syndrome (GBS)... ► Artikel lesen | |
27.05. | Hansa Biopharma Plans Restructuring | 2 | Contract Pharma | ||
26.05. | Hansa Biopharma AB: Hansa Biopharma plans restructuring to optimize resource allocation and improve operational efficiency | 240 | GlobeNewswire (Europe) | Lund, Sweden, 26 May 2025. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that it plans to restructure the organization to optimize resource allocation and improve operational... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 86,60 | +0,12 % | BioNTech Aktie: Kurssturz? - Circus, Commerzbank, Evotec, Puma und SFC Energy im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
EVOTEC | 5,812 | +0,38 % | EQS-DD: Evotec SE: Dr. Christian Wojczewski, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
27.08.2025 / 15:03... ► Artikel lesen | |
MEDIGENE | 0,073 | -1,61 % | BRISANTE Meldung setzt Medigene Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
CUREVAC | 4,586 | -0,17 % | CureVac Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
MODERNA | 20,825 | +0,14 % | Moderna, Inc.: Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism | CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at... ► Artikel lesen | |
NOVAVAX | 6,506 | +0,23 % | Novavax Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
HEIDELBERG PHARMA | 3,420 | +8,92 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharmas Partner Telix Pharmaceuticals informiert über Stand des Zulassungsantrags für sein Diagnostikum TLX250-CDx | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Finanzierung
Heidelberg Pharmas Partner Telix Pharmaceuticals informiert über Stand des Zulassungsantrags für sein Diagnostikum TLX250-CDx... ► Artikel lesen | |
CRISPR THERAPEUTICS | 45,800 | +1,33 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
4SC | 0,642 | -5,59 % | PTA-News: 4SC AG: 4SC veröffentlicht Halbjahresbericht 2025 | DJ PTA-News: 4SC AG: 4SC veröffentlicht Halbjahresbericht 2025
Unternehmensmitteilung für den Kapitalmarkt
4SC AG: 4SC veröffentlicht Halbjahresbericht 2025
Planegg-Martinsried (pta000/08.08.2025/07:30... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 496,10 | -0,02 % | How Is Regeneron's Stock Performance Compared to Other Pharma Stocks? | ||
INOVIO PHARMACEUTICALS | 2,160 | -2,70 % | INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug | ||
MAINZ BIOMED | 1,650 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt Registrierung von ColoAlert im Vereinigten Königreich bekannt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed gibt Registrierung von ColoAlert im Vereinigten Königreich bekannt
02.09.2025 / 14:01... ► Artikel lesen | |
INFLARX | 1,540 | +2,12 % | H.C. Wainwright assumes coverage on Inflarx stock with Buy rating | ||
INTELLIA THERAPEUTICS | 10,025 | +2,32 % | Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus | ||
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report |